Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T67801
|
||||
Former ID |
TTDR01148
|
||||
Target Name |
Lactotransferrin
|
||||
Gene Name |
LTF
|
||||
Synonyms |
Lactoferrin; LTF
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Bacterial infections [ICD9: 001-009, 010-018, 020-027, 030-041, 080-088, 090-099, 100-104; ICD10: A00-B99] | ||||
Diabetic foot ulcer [ICD9: 707; ICD10: L88-L89] | |||||
Function |
Transferrins are iron binding transport proteins which can bind two atoms of ferric iron in association with the binding of an anion, usually bicarbonate.lactoferroxins a, b and c have opioid antagonist activity. Lactoferroxin a shows preference for mu-receptor.
|
||||
BioChemical Class |
Peptidase
|
||||
UniProt ID | |||||
EC Number |
EC 3.4.21.-
|
||||
Sequence |
MKLVFLVLLFLGALGLCLAGRRRSVQWCAVSQPEATKCFQWQRNMRKVRGPPVSCIKRDS
PIQCIQAIAENRADAVTLDGGFIYEAGLAPYKLRPVAAEVYGTERQPRTHYYAVAVVKKG GSFQLNELQGLKSCHTGLRRTAGWNVPIGTLRPFLNWTGPPEPIEAAVARFFSASCVPGA DKGQFPNLCRLCAGTGENKCAFSSQEPYFSYSGAFKCLRDGAGDVAFIRESTVFEDLSDE AERDEYELLCPDNTRKPVDKFKDCHLARVPSHAVVARSVNGKEDAIWNLLRQAQEKFGKD KSPKFQLFGSPSGQKDLLFKDSAIGFSRVPPRIDSGLYLGSGYFTAIQNLRKSEEEVAAR RARVVWCAVGEQELRKCNQWSGLSEGSVTCSSASTTEDCIALVLKGEADAMSLDGGYVYT AGKCGLVPVLAENYKSQQSSDPDPNCVDRPVEGYLAVAVVRRSDTSLTWNSVKGKKSCHT AVDRTAGWNIPMGLLFNQTGSCKFDEYFSQSCAPGSDPRSNLCALCIGDEQGENKCVPNS NERYYGYTGAFRCLAENAGDVAFVKDVTVLQNTDGNNNEAWAKDLKLADFALLCLDGKRK PVTEARSCHLAMAPNHAVVSRMDKVERLKQVLLHQQAKFGRNGSDCPDKFCLFQSETKNL LFNDNTECLARLHGKTTYEKYLGPQYVAGITNLKKCSTSPLLEACEFLRK |
||||
Drugs and Mode of Action | |||||
Inhibitor | 3h-Indole-5,6-Diol | Drug Info | [551393] | ||
Alpha-D-Fucose | Drug Info | [551393] | |||
Alpha-D-Mannose | Drug Info | [551393] | |||
Fucose | Drug Info | [551393] | |||
Lauric Acid | Drug Info | [551393] | |||
Nimesulide | Drug Info | [551378] | |||
Nitrilotriacetic Acid | Drug Info | [551393] | |||
Parecoxib | Drug Info | [551374] | |||
Modulator | HLF 1-11 | Drug Info | [527302] | ||
Talactoferrin | Drug Info | [528590] | |||
Pathways | |||||
References | |||||
Ref 522000 | ClinicalTrials.gov (NCT00455117) Effect of Parecoxib on Post-craniotomy Pain. U.S. National Institutes of Health. | ||||
Ref 522079 | ClinicalTrials.gov (NCT00509847) A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Bacteremia Due to S. Epidermidis. U.S. National Institutes of Health. | ||||
Ref 522365 | ClinicalTrials.gov (NCT00706862) Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer. U.S. National Institutes of Health. | ||||
Ref 523284 | ClinicalTrials.gov (NCT01257126) Efficacy of Diclofenac Potassium vs Nimesulide in the Treatment of Fever and Pain in Children With Upper Respiratory Tract Infection. U.S. National Institutes of Health. | ||||
Ref 527302 | The synthetic N-terminal peptide of human lactoferrin, hLF(1-11), is highly effective against experimental infection caused by multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2004 Dec;48(12):4919-21. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.